Home › Lung Cancer › NCT05203328
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * age\>18 years * patient undergoing EBUS bronchoscopy with moderate conscious sedation. Exclusion Criteria: * subjects with previous nasal surgeries * subjects with oxygen saturation \<90% on room air prior to procedure * subjects who are pregnant * subjects with known facial fractures or recent facial trauma * subjects on any anticoagulation that cannot be discontinued prior to the procedure
About the study
Our objective is to assess whether the use of high flow nasal cannula (Vapotherm, Exeter, NH) with monitored anesthesia care (MAC) during an endobronchial ultrasound (EBUS) bronchoscopy procedure will lead to less procedure interruptions, less hypoxic episodes, shorter duration of hypoxic episodes and shorter procedural durations when compared to regular MAC using a regular nasal canula.
What is being tested
- Vapotherm (device)
- Regular nasal canula (device)
Sponsor: The Cooper Health System · Participants: 198 · Started: Feb 1, 2022
Contact the study team
- Wissam Abouzgheib, MD · Phone: (800) 826-6737
Official record on ClinicalTrials.gov — NCT05203328
Locations in the U.S.
| New Jersey | Cooper University Hospital, Camden |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.